Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

Fludarabine and busulfan becomes standard conditioning regimen for adult patients with acute myeloid leukemia (AML) or myelodysplasia syndrome (MDS). The overall relapse rate is 15\~20%. More recently, the investigators demonstrated that conditioning regimen with dual alkylating agents consistent of fludarabine, busulfan and melphalan achieved a low incidence of relapse (\<10%). This multiple-center randomize study is aim to compare the transplantation outcome in adult patients with AML/MDS undergoing allo-HSCT with conditioning regimen of Flu-Bu4 vs. FLu-Bu-Mel.

Trial Details

NCT ID
NCT05991908
Phase
PHASE3
Sponsor
Shanghai Jiao Tong University School of Medicine
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Fludarabine, busulfan and melphalan
  • Fludarabine and Busulfan
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Xiamen, Fujian, China|24.47979,118.08187
  • Nanning, Guangxi, China|22.81667,108.31667
  • Nanjin, Jiangsu, China|31.75772,121.74055
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • acute myeloid leukemia (acute promyelocytic leukemia excluded) in 1st complete remission
  • myelodysplasia syndrome with bone marrow blast \>5% and remaining less than 20% at transplantation
  • patients with HLA matched sibling donor, 9-10 matched unrelated donor or haplo-identical related donors
  • inform consent provided

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →